Market Overview - As of September 4, the Shanghai Composite Index closed at 3765.88 points, down 47.68 points, a decline of 1.25% [1] - The Shenzhen Component Index closed at 12118.70 points, down 353.29 points, a decline of 2.83% [1] - The ChiNext Index closed at 2776.25 points, down 123.12 points, a decline of 4.25% [1] Trading Activity - A total of 91 A-shares had a turnover rate exceeding 20% on September 4 [1] - Notable stocks with high turnover rates included: - Zhongke Meiling (835892) with a turnover rate of 54.90% and a price increase of 15.85% [1] - Sanwei Communication (002115) with a turnover rate of 53.57% and a price increase of 4.80% [1] - China Ruilin (603257) with a turnover rate of 53.30% and a price increase of 10.00% [1] Notable Stocks - Other stocks with significant turnover rates included: - Beifang Changlong (301357) with a turnover rate of 44.12% and a price decrease of 20.00% [1] - Chunxing Precision (002547) with a turnover rate of 44.07% and a price increase of 7.01% [1] - Gais Food (836826) with a turnover rate of 43.43% and a price increase of 16.36% [1] Summary of High Turnover Stocks - The following stocks had notable trading activity: - Haon Electric (301488) with a turnover rate of 40.72% and a price decrease of 2.50% [1] - Shangneng Electric (300827) with a turnover rate of 36.79% and a price increase of 13.32% [1] - Ningshin New Materials (839719) with a turnover rate of 36.25% and a price increase of 7.58% [1]

每经讯，2025年9月4日，北交所上市公司中科美菱（835892，收盘价：25.8元）登上龙虎榜，交易方式是连续竞价，披露原因是 当日换手率达到54.90%，成交数量1531.57万股，成交金额3.85亿元。买一席位为东方财富证券股份有限公司拉萨东环路第一证 券营业部，买入754.24万元；卖一席位为国信证券股份有限公司义乌稠江街道总部经济园证券营业部，卖出1398.39万元。 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。 每日经济新闻 ...

Group 1 - The medical device sector experienced a decline of 1.78% on September 2, with Jimin Health leading the losses [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable gainers in the medical device sector included Wende Biological, which rose by 7.61% to a closing price of 25.58, and Jinhao Medical, which increased by 6.66% to 29.48 [1] Group 2 - Jimin Health saw a significant drop of 10.02%, closing at 11.40, with a trading volume of 1.0859 million shares and a transaction value of 1.331 billion [2] - Other notable decliners included Rejing Biological, which fell by 8.72% to 186.79, and Yikang Haosheng, which decreased by 7.71% to 34.24 [2] - The medical device sector experienced a net outflow of 1.23 billion from major funds, while retail investors contributed a net inflow of 1.011 billion [2]

证券代码：835892 证券简称：中科美菱 公告编号：2025-075 中科美菱低温科技股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、授权募集资金现金管理情况 （二）使用闲置募集资金投资现金管理产品的说明 （一）现金管理的审议情况 为提高募集资金使用效率，本着股东利益最大化的原则，公司第三届董事会 第三十一次会议、2024 年第二次临时股东大会，审议通过了《关于使用部分募 集资金进行现金管理的议案》，在确保不影响募集资金投资项目正常实施以及确 保募集资金安全的前提下，公司及下属子公司使用最高不超过 25,000 万元（该 额度可以循环滚动使用）闲置募集资金购买安全性高、流动性好、低风险、可保 障本金安全的理财产品，使用期限为自 2024 年第二次临时股东大会审议通过之 日起 12 个月内有效。 具体内容详见公司于 2024 年 12 月 11 日、12 月 27 日北京证券交易所网站 披露的《关于使用部分募集资金进行现金管理的公告》（公 ...

证券代码：835892 证券简称：中科美菱 公告编号：2025-074 中科美菱低温科技股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、授权募集资金现金管理情况 （一）现金管理的审议情况 为提高募集资金使用效率，本着股东利益最大化的原则，公司第三届董事会 第三十一次会议、2024 年第二次临时股东大会，审议通过了《关于使用部分募 集资金进行现金管理的议案》，在确保不影响募集资金投资项目正常实施以及确 保募集资金安全的前提下，公司及下属子公司使用最高不超过 25,000 万元（该 额度可以循环滚动使用）闲置募集资金购买安全性高、流动性好、低风险、可保 障本金安全的理财产品，使用期限为自 2024 年第二次临时股东大会审议通过之 日起 12 个月内有效。 具体内容详见公司于 2024 年 12 月 11 日、12 月 27 日北京证券交易所网站 披露的《关于使用部分募集资金进行现金管理的公告》（公告编号：2024-070）、 《2024 年第 ...

中科美菱低温科技股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、授权募集资金现金管理情况 （一）现金管理的审议情况 为提高募集资金使用效率，本着股东利益最大化的原则，公司第三届董事会 第三十一次会议、2024 年第二次临时股东大会，审议通过了《关于使用部分募 集资金进行现金管理的议案》，在确保不影响募集资金投资项目正常实施以及确 保募集资金安全的前提下，公司及下属子公司使用最高不超过 25,000 万元（该 额度可以循环滚动使用）闲置募集资金购买安全性高、流动性好、低风险、可保 障本金安全的理财产品，使用期限为自 2024 年第二次临时股东大会审议通过之 日起 12 个月内有效。 证券代码：835892 证券简称：中科美菱 公告编号：2025-073 根据《北京证券交易所股票上市规则》中相关规定，交易的成交金额占上市 公司最近一期经审计净资产的 10%以上，且超过 1,000 万元的应当予以披露；上 市公司连续 12 个月滚动发生理财的， ...

Group 1 - The company reported a revenue of 150 million yuan in the first half of 2025, representing a year-on-year growth of 2.16%, and a net profit attributable to shareholders of 11.0458 million yuan, up 5.94% year-on-year [1] - The global low-temperature storage industry is experiencing increased competition and a shift in market dynamics, prompting the company to focus on the life sciences sector and enhance operational capabilities [1][3] - The company aims to improve management efficiency and service levels while driving business scale and profitability through innovation in product development and channel upgrades [1] Group 2 - Established in 2002, the company is one of the early entrants in the ultra-low temperature storage for biological cells, offering a range of products including low-temperature storage boxes and biological safety cabinets [2] - The company's products are widely used in various sectors such as medical systems, blood systems, disease control, and biopharmaceutical enterprises, contributing to its recognition as a high-tech enterprise and a national-level specialized "little giant" [2] - The company has received numerous awards, including the National Technology Invention Award (second class) and the China International Industrial Expo Silver Award, highlighting its innovation and contributions to the industry [2] Group 3 - The company adheres to a business philosophy centered on technology, product, market orientation, and customer focus, achieving breakthroughs in core refrigeration technology for the biomedical field [3] - It implements a product synergy strategy that focuses on the entire sample ecosystem and aims to become a global leader in customized system solutions for the life sciences sector [3]

Core Viewpoint - Zhongke Meiling's stock price increased by 2.47% to 21.98 yuan, indicating positive market sentiment towards the company [1] Company Performance - Zhongke Meiling reported a revenue of 150 million yuan for the first half of 2025, representing a year-on-year growth of 2.16% [1] - The net profit attributable to shareholders reached 11.0458 million yuan, showing a year-on-year increase of 5.94% [1] - The company's non-recurring net profit was 6.8064 million yuan, which reflects a significant year-on-year growth of 158.29% [1] Industry Position - Zhongke Meiling operates in the specialized equipment manufacturing sector and is recognized as a national-level "little giant" enterprise focusing on specialized and innovative technologies [1] - The company specializes in the research and manufacturing of biomedical low-temperature storage equipment, providing solutions for medical and scientific research fields [1]

Group 1 - The core point of the article is that Zhongke Meiling reported its financial results for the first half of 2025, showing a slight increase in revenue and net profit compared to the previous year [2] - The company achieved an operating income of 150,225,865.88 yuan, representing a year-on-year growth of 2.16% [2] - The net profit attributable to shareholders of the listed company was 11,045,823.50 yuan, reflecting a year-on-year increase of 5.94% [2]

Group 1 - The core point of the article is that Zhongke Meiling announced the approval of several proposals, including the 2025 semi-annual report and its summary, during the third meeting of the fourth board of directors [2] Group 2 - The announcement was made on the evening of August 15 [2] - The meeting involved the review and approval of important financial documents [2] - The company is preparing for its future financial disclosures [2]